Cancer Drug Approvals

FDA's Office of Hematology and Oncology Drug Products is committed to facilitating rapid development, review, and action on promising new cancer therapies. Scientists within OODP are working intensively on incorporating innovations in pharmacogenomics, bioinformatics, and clinical trial design into the drug development process. These efforts will provide the basis for accelerating introduction of new treatments for cancer into practice.

• What's New from the Office of Hematology and Oncology Drug Products